Active monitoring seems to be the safest and most comfortable option for most men with localised prostate cancer according to findings of the big randomised ProtecT study from the UK. Surgery and rad
OXFORD, UK—The massive ten-year randomized Prostate Testing for Cancer and Treatment (ProtecT) trial—published in the New England Journal of Medicine—of treatment for PSA-detected localized prostate cancer found that in most patients radical prostatectomy and radiotherapy did not reduce prostate-specific or overall mortality as compared with “active monitoring”, and that, overall, PSA-detected prostate cancer killed very rarely!
The Audio Journal of Oncology hears from lead author Freddie Hamdy MBChB, MD, FRCS, Nuffield Professor of Surgery and Professor of Urology at the University of Oxford.
YouTube link:
Audio Medica link:
iTunes link: